SWM
ALNY icon

Selective Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Selective Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-88
Closed -$13K – 311
2020
Q2 		$13K Hold
88
– – 0.01% 213
2020
Q1 		$10K Hold
88
– – 0.02% 152
2019
Q4 		$10K Hold
88
– – 0.01% 158
2019
Q3 		$7K Buy
+88
New +$6.96K 0.01% 190

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Selective Wealth Management's ALNY Position: Q3 2020 in Review

Selective Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 88 shares — an estimated $13K sold.

Selective Wealth Management first reported a position in ALNY in Q3 2019 and held it in 4 quarters. The position peaked at $13K in Q2 2020. 357 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • Selective Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Selective Wealth Management sold 88 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $13K.
  • Selective Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Selective Wealth Management's Alnylam Pharmaceuticals position peaked at $13K in Q2 2020.
  • 357 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Selective Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.